A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

Abstract

The aim of this study was to investigate the capacity of an HPV16 E6/E7 synthetic overlapping long-peptide vaccine to stimulate the HPV16-specific T-cell response, to enhance the infiltration of HPV16-specific type 1 T cells into the lesions of patients with HPV16+ high-grade cervical squamous intraepithelial lesion (HSIL) and HPV clearance. This was a placebo-controlled randomized phase II study in patients with HPV16-positive HSIL. HPV16-specific T-cell responses were determined pre- and post-vaccination by ELISPOT, proliferation assay and cytokine assays in PBMC and HSIL-infiltrating lymphocytes, and delayed-type hypersensitivity skin tests. Motivational problems of this patient group to postpone treatment of their premalignant lesions affected the inclusion rates and caused the study to stop prematurely. Of the accrued patients, 4 received a placebo and 5 received 1–2 vaccinations. Side effects mainly were flu-like symptoms and injection site reactions. A strong HPV-specific IFNγ-associated T-cell response was detected by ELISPOT in all vaccinated patients. The outcome of the skin tests correlated well with the ELISPOT analysis. The cytokine profile associated with HPV16-specific proliferation varied from robust type 1 to dominant type 2 responses. No conclusions could be drawn on vaccine-enhanced T-cell infiltration of the lesion, and there was no HPV clearance at the time of LEEP excision. Thus, vaccination of HSIL patients results in increased HPV16-specific T-cell immunity. Further development of this type of treatment relies on the ability to motivate patients and in the reduction in the side effects.Electronic supplementary materialThe online version of this article (doi:10.1007/s00262-012-1292-7) contains supplementary material, which is available to authorized users.

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope

“…The vaccines were composed of clinical-grade antigenic peptides, CpG-B 7909/PF-3512676 (Pfizer Inc.) and Montanide ISA-51 (Seppic SA) and were administered subcutaneously (s.c.). Antigenic peptides were the 30-amino acid long NY-ESO-1 79-108 peptide (for all patients), and the short HLA-A2-restricted peptides Melan-A [26][27][28][29][30][31][32][33][34][35] (native EAAGIGILTV), Melan-A 26-35(A27L) (analog ELAGIGILTV) and MAGE-A10 254-262 (GLYDGMEHL) (only for HLA-A2 positive patients). Vaccinations were administered in cycles of 4 mo vaccines with intervals of 2 mo between the cycles (Fig.…”

Advances in the study of HLA-restricted epitope vaccines

“…Development of this type of treatment relies on the ability to motivate patients and in the reduction of the side effects. 71 A multi-epitope chimeric DNA vaccine that expresses 25 glycoprotein epitopes from SEOV, HTNV and PUUV (designated as SHP chimeric gene) from hantavirus was constructed by Zhao et al 72 The vaccination of BALB/c mice with the SHP multi-epitope chimeric DNA vaccine led to a marked dramatic augmentation of the humoral and cellular responses.…”

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

“…In another group of women with high-grade cervical squamous intraepithelial lesions, this vaccine did not induce iniltration of HPV 16-speciic T cells into the lesions or HPV clearance [97]. In a third group of patients with HPV 16-positive advanced or recurrent gynecological carcinoma, this vaccine was given with the adjuvant Montanide ISA-51.…”